Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

ColoSTEM Dx Kit: Innovative Alliance of Cancer Stem Cells and Glycosylation for Earlier Prediction of Colon Cancer Aggressiveness and Prognosis

Version 1 : Received: 29 October 2021 / Approved: 4 November 2021 / Online: 4 November 2021 (09:23:14 CET)

How to cite: Blondy, S.; Durand, S.; Lacroix, A.; Christou, N.; Bouchaud, C.; Peyny, M.; Battu, S.; Chaunavel, A.; Carre, V.; Jauberteau, M.; Lalloue, F.; Mathonnet, M. ColoSTEM Dx Kit: Innovative Alliance of Cancer Stem Cells and Glycosylation for Earlier Prediction of Colon Cancer Aggressiveness and Prognosis. Preprints 2021, 2021110096 (doi: 10.20944/preprints202111.0096.v1). Blondy, S.; Durand, S.; Lacroix, A.; Christou, N.; Bouchaud, C.; Peyny, M.; Battu, S.; Chaunavel, A.; Carre, V.; Jauberteau, M.; Lalloue, F.; Mathonnet, M. ColoSTEM Dx Kit: Innovative Alliance of Cancer Stem Cells and Glycosylation for Earlier Prediction of Colon Cancer Aggressiveness and Prognosis. Preprints 2021, 2021110096 (doi: 10.20944/preprints202111.0096.v1).

Abstract

Nowadays, colon cancer prognosis still difficult to predict, especially in the early stages. Recurrences remain elevated, even in the early stages after curative surgery. Carcidiag Biotechnologies has developed an immunohistochemistry (IHC) kit called ColoSTEM Dx, based on a MIX of biotinylated plant lectins that specifically detects colon cancer stem cells (CSCs) through glycan patterns that they specifically (over)express. A retrospective clinical study was carried out on tumor tissues from 208 non-treated and 21 treated patients with colon cancer, that were stained by IHC with the MIX. Clinical performances of the kit were determined, and prognostic and predictive values were evaluated. With 78.3% and 70.6% of diagnostic sensitivity and specificity respectively, our kit shows great clinical performances. Moreover, patient prognosis is significantly poorer when the MIX staining is “High” compared to “Low”, especially at 5-years of overall survival and for early stages. The ColoSTEM Dx kit allows an earlier and a more precise determination of patients’ outcome. Thus, it affords an innovating clinical tool for predicting tumor aggressiveness earlier and determining prognosis value regarding therapeutic response in colon cancer patients.

Keywords

Aggressiveness; biomarker; cancer stem cells; diagnosis; colon cancer; glycan; immunohistochemistry; lectin; prognosis

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.